RADICAVA ORS® has been evaluated in 7+ medical studies
RADICAVA ORS® can be taken orally or via feeding tube, without the need for dose adjustment
5 mL dose may take only a few minutes to administer on treatment daysb,c (see footnote)
RADICAVA ORS® should be taken in the morning on an empty stomach after overnight fasting
RADICAVA ORS® contains sorbitol, an ingredient with a mildly sweet taste
RADICAVA ORS® & RADICAVA® IV?
RADICAVA ORS® (edaravone) is an ORAL administration option of RADICAVA® (edaravone), an ALS treatment shown to slow the loss of physical function.
78% of patients who started on RADICAVA® from June 2022 - April 2023 stayed on treatment 3 months or more.b (see footnote)
Have questions as you learn about RADICAVA®?
Call a JourneyMate Resource Specialist at 1-855-457-6968 between 9 AM and 9 PM ET, Monday through Friday.
RADICAVA ORS® Is Formulated to Fit Your Life's Routines
Prioritizing the needs of those with ALS
Building on the legacy of RADICAVA®, Mitsubishi Tanabe Pharma America is prioritizing helping people with ALS by continuing to invest in research with edaravone to help meet the needs of the ALS community.
Edaravone has been studied for over a decade in research and development.
Wide experience with RADICAVA®
RADICAVA® has been used to treat 12,500+ patients with approximately 1.4 million+ days of therapy since approved by the FDA.a,e (see footnote)
RADICAVA® has been prescribed by nearly 2000+ healthcare providers.a (see footnote)
ALS can progress rapidly. Beginning treatment with RADICAVA ORS® or RADICAVA® IV can be an important step to managing your ALS.
RADICAVA ORS® Is an Oral Form of RADICAVA (edaravone)
RADICAVA® has been shown to slow the loss of physical function by 33% (approximately one-third) vs placebo.
This means a 33% less decline in physical function for patients on RADICAVA® vs those on placebo.
In the clinical study, RADICAVA® slowed the loss of physical function as measured by the ALSFRS-R. At 24 weeks (about 6 months), patients who did not receive RADICAVA® declined more rapidly in physical function, having lost an average of 2.49 points more than those who received RADICAVA®.
Individual results may vary.
On the ALSFRS-R, the fewer points lost, the greater the physical function.
Patients on RADICAVA® lost fewer ALSFRS-R points on average at 6 months.
3X as many patients given RADICAVA® lost 2 or less points
(39.1% RADICAVA® vs 13.2% placebo)
A similar number of patients in both treatment arms lost 3 to 10 points (37/69 with RADICAVA® and 43/68 with placebo).
3X as many patients given placebo lost 11 or less points
(23.5% placebo vs 7.2% RADICAVA®)
Over 90% of patients in each group were also being treated with riluzole.
When it came to RADICAVA®, I extensively researched any information available and had in-depth discussions with my neurologist and we decided it was the right choice for me.
Understanding the Safety Profile of RADICAVA ORS® and RADICAVA® IV
RADICAVA ORS® is the oral formulation of RADICAVA® and has a similar safety profile.
The safety profiles of RADICAVA® and RADICAVA ORS® were established in 500+ patients with ALS in multiple clinical studies.
Side effect profile:
The safety of the IV formulation of RADICAVA® was evaluated in multiple placebo-controlled studies in 184 patients with ALS
RADICAVA ORS® was generally well tolerated in a 6-month clinical study of 185 patients with ALS
The most common side effects were bruising (contusion) [15%], problems with walking (gait disturbance) [13%], and headache [10%]. Fatigue was also reported in 7.6% of patients taking RADICAVA ORS®
These are not all of the possible side effects with RADICAVA® or RADICAVA ORS®.
RADICAVA ORS® and RADICAVA® IV have no known drug interactions
Fewer than 6% (11/185) of patients discontinued RADICAVA ORS® because of side effects in the 6-month safety study in 185 patients with ALS
Approximately 1% (2/185) of patients discontinued RADICAVA ORS® due to gastrointestinal side effects (diarrhea and trouble swallowing)
Other reasons for discontinuation in ~1% (2/185) of patients included respiratory failure and muscular weakness
RADICAVA ORS® and RADICAVA® have been used in clinical studies with other approved drugs for ALS, including riluzole
Be sure to tell your doctor if you are allergic to other medications and share all of the medications you are taking
The Prescribing Information has no requirement for monitoring kidney or liver function.
RADICAVA® and RADICAVA ORS® may cause serious side effects including hypersensitivity (allergic) reactions and sulfite allergic reactions.
Make sure to tell your doctor:
If you have asthma
If you are allergic to other medications
If you are pregnant or intend to become pregnant
If you are breastfeeding or intend to breastfeed
All of the medications you are taking
Please see additional Important Safety Information.
Understanding Your Treatment With RADICAVA ORS®
Watch this video to learn more about this oral ALS treatment option.
You can also see a Clinical Educator share important information in this video: Starting Treatment With RADICAVA ORS®
Get answers to FAQs about RADICAVA ORS® and RADICAVA® IV.
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of July 2023. Not independently verified. Return to content
bPatients who started RADICAVA ORS® or RADICAVA® IV between June 2022 and April 2023 and continued for 3 months or more through July 2023. Return to content
cThe initial treatment cycle starts with daily dosing of RADICAVA ORS® for 14 days followed by a 14-day drug-free period. Subsequent treatment cycles include daily dosing 10 out of 14 days followed by a 14-day drug-free period. Return to content
dUse the provided 5 mL syringe that comes with the product. Do not use a household teaspoon to measure your medication. Return to content
eDays of therapy based on number of RADICAVA ORS® and RADICAVA® IV cartons sold as of July 2023. Each carton represents a day’s supply of therapy. Return to content
FDA=Food and Drug Administration; IV=intravenous.